AU748034B2 - Parenteral formulations comprising carbamazepine or its derivatives - Google Patents

Parenteral formulations comprising carbamazepine or its derivatives Download PDF

Info

Publication number
AU748034B2
AU748034B2 AU96298/98A AU9629898A AU748034B2 AU 748034 B2 AU748034 B2 AU 748034B2 AU 96298/98 A AU96298/98 A AU 96298/98A AU 9629898 A AU9629898 A AU 9629898A AU 748034 B2 AU748034 B2 AU 748034B2
Authority
AU
Australia
Prior art keywords
parenteral formulation
glucose
water
parenteral
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU96298/98A
Other languages
English (en)
Other versions
AU9629898A (en
Inventor
Peter Van Hoogevest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU9629898A publication Critical patent/AU9629898A/en
Application granted granted Critical
Publication of AU748034B2 publication Critical patent/AU748034B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU96298/98A 1997-10-09 1998-10-07 Parenteral formulations comprising carbamazepine or its derivatives Ceased AU748034B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9721497.7A GB9721497D0 (en) 1997-10-09 1997-10-09 Organic compounds
GB9721497 1997-10-09
PCT/EP1998/006382 WO1999018966A1 (en) 1997-10-09 1998-10-07 Parenteral formulations comprising carbamazepine or its derivatives

Publications (2)

Publication Number Publication Date
AU9629898A AU9629898A (en) 1999-05-03
AU748034B2 true AU748034B2 (en) 2002-05-30

Family

ID=10820342

Family Applications (1)

Application Number Title Priority Date Filing Date
AU96298/98A Ceased AU748034B2 (en) 1997-10-09 1998-10-07 Parenteral formulations comprising carbamazepine or its derivatives

Country Status (31)

Country Link
US (2) US6316417B1 (enExample)
EP (1) EP1033988B1 (enExample)
JP (2) JP2001519395A (enExample)
KR (1) KR100760326B1 (enExample)
CN (1) CN1210032C (enExample)
AR (1) AR015465A1 (enExample)
AT (1) ATE257383T1 (enExample)
AU (1) AU748034B2 (enExample)
BR (1) BR9812861A (enExample)
CA (1) CA2304661C (enExample)
CO (2) CO4950520A1 (enExample)
CZ (1) CZ298900B6 (enExample)
DE (1) DE69821024T2 (enExample)
DK (1) DK1033988T3 (enExample)
ES (1) ES2214738T3 (enExample)
GB (1) GB9721497D0 (enExample)
HU (1) HU226106B1 (enExample)
ID (1) ID24134A (enExample)
IL (1) IL135123A0 (enExample)
MY (1) MY122129A (enExample)
NO (1) NO327263B1 (enExample)
NZ (1) NZ503526A (enExample)
PE (1) PE121998A1 (enExample)
PL (1) PL192287B1 (enExample)
PT (1) PT1033988E (enExample)
RU (1) RU2242231C2 (enExample)
SK (1) SK286253B6 (enExample)
TR (1) TR200000870T2 (enExample)
TW (1) TW584563B (enExample)
WO (1) WO1999018966A1 (enExample)
ZA (1) ZA989183B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2007041524A2 (en) * 2005-09-30 2007-04-12 Ovation Pharmaceuticals, Inc. Novel parenteral carbamazepine formulation
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
KR101478164B1 (ko) * 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
CN101711739B (zh) * 2008-10-08 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 卡马西平的口服药物组合物
CN105726466A (zh) * 2014-12-10 2016-07-06 辽宁药联制药有限公司 一种奥卡西平注射剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2033118A1 (en) * 1989-12-27 1991-06-28 Anne-Francoise Steulet Intravenous solutions for status epileptious
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
ES2081965T3 (es) * 1989-12-27 1996-03-16 Ciba Geigy Ag Dispositivo para homogenizar la distribuccion no homogenea de la luz de un haz de rayos laser.
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
RU2020972C1 (ru) * 1991-02-07 1994-10-15 Мегдятов Рашид Салехович Способ лечения невралгии тройничного нерва
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2033118A1 (en) * 1989-12-27 1991-06-28 Anne-Francoise Steulet Intravenous solutions for status epileptious
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine

Also Published As

Publication number Publication date
US6316417B1 (en) 2001-11-13
RU2242231C2 (ru) 2004-12-20
PT1033988E (pt) 2004-05-31
HUP0004362A3 (en) 2006-06-28
KR20010072533A (ko) 2001-07-31
ES2214738T3 (es) 2004-09-16
CA2304661C (en) 2007-12-11
SK5052000A3 (en) 2000-12-11
PL339446A1 (en) 2000-12-18
PE121998A1 (es) 1999-12-08
BR9812861A (pt) 2000-08-08
ID24134A (id) 2000-07-06
NO20001730L (no) 2000-04-04
SK286253B6 (sk) 2008-06-06
EP1033988A1 (en) 2000-09-13
KR100760326B1 (ko) 2007-09-20
CZ298900B6 (cs) 2008-03-05
TW584563B (en) 2004-04-21
DE69821024T2 (de) 2004-10-28
CO4950520A1 (es) 2000-09-01
HK1031824A1 (en) 2001-06-29
NO20001730D0 (no) 2000-04-04
AR015465A1 (es) 2001-05-02
HU226106B1 (en) 2008-04-28
ZA989183B (en) 1999-04-09
CN1210032C (zh) 2005-07-13
GB9721497D0 (en) 1997-12-10
JP2005281314A (ja) 2005-10-13
CO5090854A1 (es) 2001-10-30
NZ503526A (en) 2003-01-31
IL135123A0 (en) 2001-05-20
EP1033988B1 (en) 2004-01-07
HUP0004362A2 (hu) 2001-08-28
US20020055503A1 (en) 2002-05-09
DK1033988T3 (da) 2004-04-13
DE69821024D1 (de) 2004-02-12
CA2304661A1 (en) 1999-04-22
ATE257383T1 (de) 2004-01-15
NO327263B1 (no) 2009-05-25
PL192287B1 (pl) 2006-09-29
MY122129A (en) 2006-03-31
US6458770B1 (en) 2002-10-01
TR200000870T2 (tr) 2000-10-23
CN1274286A (zh) 2000-11-22
AU9629898A (en) 1999-05-03
CZ20001279A3 (cs) 2000-07-12
WO1999018966A1 (en) 1999-04-22
JP2001519395A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
EP3363428B1 (en) Perfusion dosage form
AU777619B2 (en) Suspension comprising oxcarbazepine
US20180028498A1 (en) A pharmaceutical composition for the parenteral administration of melatonin, and a process for its preparation
KR20150132835A (ko) 변형된 가요성 플라스틱 용기에서 즉시 사용가능한 공용매 약학 조성물
US6458770B1 (en) Parenteral formulations comprising carbamazepine or its derivatives
HK1031824B (en) Parenteral formulations comprising 10-hydroxy-10, 11-tetrahydrocarbamazepine, water and glucose
MXPA00003413A (en) Parenteral formulations comprising carbamazepine or its derivatives
WO2017149552A1 (en) Parenteral dosage form of amiodarone
AU2004203644B2 (en) Pharmaceutical compositions
HK1050474B (en) Suspension comprising oxcarbazepine
HK1070267A (en) Suspension comprising oxcarbazepine
WO2000067753A1 (en) Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate)
AU2014203121B2 (en) Concentrate esmolol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)